RS Research Company
RS Research is a biotechnology start-up that specializes in developing nanomedicines to treat cancer patients. They have a unique drug delivery platform called Sagitta® that allows for the rapid development of targeted nanomedicines for multiple indications. They also offer preclinical services to industrial and academic partners, with expertise in biosimilar characterization and in vivo experiment design. RS Research has a GMP certified production facility that is capable of producing clinical batch-size contracts for cytotoxic services in the region.
Headquarters:
Vaud
Estimated Revenue:
over 47 billion U.S. dollars
Industry:
PharmTech